32.7 C
Vientiane
Wednesday, August 20, 2025
spot_img
Home Blog Page 99

ZKH Group Limited to Announce Second Quarter 2025 Financial Results on Friday, August 22, 2025

SHANGHAI, Aug. 8, 2025 /PRNewswire/ — ZKH Group Limited (“ZKH” or the “Company”) (NYSE: ZKH), a leading maintenance, repair and operations (“MRO”) procurement service platform in China, today announced that it will release its unaudited financial results for the second quarter of 2025, on Friday, August 22, 2025, before the open of the U.S. markets.

The Company’s management will hold an earnings conference call on Friday, August 22, 2025 at 8:00 A.M. U.S. Eastern Time (8:00 P.M. Beijing/Hong Kong Time) to discuss the financial results. Listeners may access the call by dialing the following numbers:

United States (toll free):

+1-888-317-6003

International:

+1-412-317-6061

Mainland China (toll free):

400-120-6115

Hong Kong (toll free):

800-963-976

Hong Kong:

+852-5808-1995

Access Code:

6971877

A replay of the conference call will be accessible by phone one hour after the conclusion of the live call at the following numbers, until August 29, 2025:

United States:

+1-877-344-7529

International:

+1-412-317-0088

Replay Access Code:       

5489224

A live and archived webcast of the conference call will also be available on the Company’s investor relations website at https://ir.zkh.com.

About ZKH Group Limited

ZKH Group Limited (NYSE: ZKH) is a leading MRO procurement service platform in China, underpinned by robust supply chain capabilities and dedicated to serving customers globally through a product-led, agentic AI-driven approach. Through its primary online platforms, the ZKH platform, the GBB platform and the Northsky platform, along with innovative technology and extensive industry expertise, the Company provides bespoke MRO procurement solutions to a diverse and loyal customer base. These solutions encompass hyper-personalized product curation from a comprehensive selection of quality products at competitive prices. Additionally, the Company ensures timely and reliable product delivery through professional fulfillment services. By focusing on reducing procurement costs and addressing management efficiency challenges, ZKH is transforming the opaque MRO procurement process and empowering all stakeholders across the value chain.

For more information, please visit https://ir.zkh.com.

For investor and media inquiries, please contact:

In China:

ZKH Group Limited
IR Department
E-mail: IR@zkh.com

Piacente Financial Communications
Hui Fan
Tel: +86-10-6508-0677
E-mail: zkh@thepiacentegroup.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: zkh@thepiacentegroup.com

X Financial to Report Second Quarter 2025 Financial Results on August 19, 2025

SHENZHEN, China, Aug. 8, 2025 /PRNewswire/ — X Financial (NYSE: XYF) (the “Company”), a leading online personal finance company in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2025, before the open of U.S. markets on Tuesday, August 19, 2025.

X Financial’s management team will host an earnings conference call at 8:30 AM U.S. Eastern Time on Tuesday, August 19, 2025 (8:30 PM Beijing / Hong Kong Time on the same day).

Dial-in details for the earnings conference call are as follows:

United States:

1-888-346-8982

Hong Kong:

852-301-84992

Mainland China:

4001-201203

International:

1-412-902-4272

Passcode:

X Financial

Please dial in ten minutes before the call is scheduled to begin and provide the passcode to join the call.

A replay of the conference call may be accessed by phone at the following numbers until August 26, 2025:

United States:

1-877-344-7529

International:

1-412-317-0088

Passcode:

1404098

Additionally, a live and archived webcast of the conference call will be available at https://ir.xiaoyinggroup.com.

About X Financial

X Financial is a leading online personal finance company in China. The Company is committed to connecting borrowers on its platform with its institutional funding partners. With its proprietary big data-driven technology, the Company has established strategic partnerships with financial institutions across multiple areas of its business operations, enabling it to facilitate loans to prime borrowers under a robust risk assessment and control system.

For more information, please visit: https://ir.xiaoyinggroup.com.

For more information, please contact:

X Financial
Mr. Frank Fuya Zheng
Mr. Noah Kauffman
E-mail: ir@xiaoying.com 

Christensen
In China
Mr. Rene Vanguestaine
Phone: +86-178-1749 0483
E-mail: rene.vanguestaine@christensencomms.com 

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com 

 

ChipMOS REPORTS JULY 2025 REVENUE

HSINCHU, Aug. 8, 2025 /PRNewswire-FirstCall/ — ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS), an industry leading provider of outsourced semiconductor assembly and test services (“OSAT”), today reported its unaudited consolidated revenue for the month of July 2025. All U.S. dollar figures cited in this press release are based on the exchange rate of NT$29.91 to US$1.00 as of July 31, 2025.

Revenue for the month of July 2025 was NT$1,965.9 million or US$65.7 million, representing an increase of 6.3% from June 2025, and a decrease of 4.7% from July 2024.  The Company noted it is benefitting from continued favorable pricing and volume trends for memory products. While not a material impact year to date, the Company continues to monitor the evolving tariff situation and plans to adjust accordingly to mitigate the impact and to best support customers.

Consolidated Monthly Revenues (Unaudited)

July 2025

June 2025

July 2024

MoM Change

YoY Change

Revenues

   (NT$ million)

1,965.9

1,849.7

2,063.4

6.3 %

-4.7 %

Revenues

   (US$ million)

65.7

61.8

69.0

6.3 %

-4.7 %

About ChipMOS TECHNOLOGIES INC.:

ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS) (www.chipmos.com) is an industry leading provider of outsourced semiconductor assembly and test services. With advanced facilities in Hsinchu Science Park, Hsinchu Industrial Park and Southern Taiwan Science Park in Taiwan, ChipMOS is known for its track record of excellence and history of innovation. The Company provides end-to-end assembly and test services to leading fabless semiconductor companies, integrated device manufacturers and independent semiconductor foundries serving virtually all end markets worldwide. 

Forward-Looking Statements:

This press release may contain certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future’ or similar expressions or by discussion of, among other things, strategies, goals, plans or intentions. These statements may include financial projections and estimates and their underlying assumptions, statements regarding tariffs and the imposition of potential new tariffs that affect our products or operations, government policies, global trade environments, pricing, plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Actual results may differ materially in the future from those reflected in forward-looking statements contained in this document, due to various factors. Further information regarding these risks, uncertainties and other factors are included in the Company’s most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s other filings with the SEC.

Contacts:

In Taiwan

Jesse Huang

ChipMOS TECHNOLOGIES INC.

+886-6-5052388 ext. 7715

IR@chipmos.com

In the U.S.

David Pasquale

Global IR Partners

+1-914-337-8801

dpasquale@globalirpartners.com

 

China Yuchai International Announces Unaudited 2025 First Half-Year Financial Results

SINGAPORE, Aug. 8, 2025 /PRNewswire/ — China Yuchai International Limited (NYSE: CYD) (“China Yuchai” or the “Company”), one of the largest powertrain solution manufacturers through its main operating subsidiary in China, Guangxi Yuchai Machinery Company Limited (“Yuchai”), announces today its unaudited consolidated financial results for the first half-year ended June 30, 2025 (“1H 2025”).  The financial information presented herein for 1H 2025 and the first half-year of 2024 (“1H 2024”) are reported using the IFRS accounting standards (“IFRS”) as issued by the International Accounting Standards Board.

Financial Highlights for 1H 2025

  • Revenue increased by 34.0% to RMB 13.8 billion (US$ 1.9 billion) compared with RMB 10.3 billion in 1H 2024;
  • Gross profit increased by 30.3% to RMB 1.8 billion (US$ 257.0 million) compared with RMB 1.4 billion in 1H 2024. Gross margin was 13.3% in 1H 2025 compared with 13.7% in 1H 2024; 
  • Operating profit increased by 42.3% to RMB 621.7 million (US$ 86.9 million) compared with RMB 436.9 million in 1H 2024; 
  • Profit for the period rose by 58.9% to RMB 534.8 million (US$ 74.7 million) compared with RMB 336.6 million in 1H 2024; 
  • Basic and diluted earnings per share were 65.8% higher at RMB 9.75 (US$ 1.36) compared with RMB 5.88 in 1H 2024; 
  • Total number of engines sold increased by 29.9% to 250,396 units compared with 192,743 units in 1H 2024. 

Revenue was RMB 13.8 billion (US$ 1.9 billion) compared with RMB 10.3 billion in 1H 2024.

The total number of engines sold in 1H 2025 increased by 29.9% to 250,396 units compared with 192,743 units in 1H 2024.  The increase was mainly due to higher sales in almost every engine segment.  The Company’s truck and bus engine unit sales rose by 38.0% year over year in 1H 2025, despite a decline of 2.6% witnessed in the commercial vehicle markets (excluding gasoline- and electric-powered vehicles) as reported by the China Association of Automobile Manufacturers (“CAAM”).  The Company’s truck engine sales were up 44.3% year over year, compared with negative growth of 1.8% in truck market unit sales as reported by CAAM.  In particular, heavy- and light-duty truck engine unit sales were 40.7% and 82.1% higher year over year, in contrast to CAAM market unit sales growth of negative 2.8% and 1.3%, respectively.  The Company’s heavy-duty bus engine sales rose by 14.4%, compared to a CAAM bus market unit sales reduction of 13.5%.  Overall bus engine unit sales increased by 8.9% in 1H 2025, in contrast to a 7.5% decline in overall bus market unit sales, as reported by CAAM.

Engine sales to off-road markets increased by 17.5% year over year in 1H 2025.  Engine sales to the marine and power generation markets drove the off-road segment growth with a 31.5% year over year increase.  Sales for industrial applications rose by 27.2% year over year in 1H 2025, while engine sales for agricultural equipment experienced modest growth in 1H 2025.

Gross profit increased by 30.3% to RMB 1.8 billion (US$ 257.0 million), from RMB 1.4 billion in 1H 2024. The increase was mainly due to higher sales volume.  Overall gross margin was 13.3% in 1H 2025 compared with 13.7% in 1H 2024.  

Other operating income increased by 27.2% to RMB 221.4 million (US$ 30.9 million) compared with RMB 174.1 million in 1H 2024.  The increase was mainly driven by the recognition of technology licensing fees and a higher rebate on value-added taxes.  

Research and development (“R&D”) expenses increased by 21.1% to RMB 476.7 million (US$ 66.6 million) compared with RMB 393.6 million in 1H 2024, due to higher experimental and personnel costs.  Total R&D expenditures, including capitalized costs, were RMB 551.7 million (US$ 77.1 million), representing 4.0% of revenue in 1H 2025, as compared to RMB 463.2 million and 4.5% of revenue in 1H 2024.

Selling, general and administrative (“SG&A”) expenses increased by 27.4% to RMB 962.5 million (US$ 134.5 million) from RMB 755.7 million in 1H 2024. This increase was mainly due to higher personnel expenses compared with the same period last year.  SG&A expenses represented 7.0% of revenue for 1H 2025 compared with 7.3% for 1H 2024.

Operating profit increased by 42.3% to RMB 621.7 million (US$ 86.9 million) compared to RMB 436.9 million in 1H 2024.  The operating margin was 4.5%, in contrast to 4.2% in 1H 2024. Higher operating profit and operating margin were achieved by increased sales and gross profit combined with lower growth in operating expenses.

Finance costs decreased by 21.3% to RMB 32.2 million (US$ 4.5 million) from RMB 40.9 million in 1H 2024, primarily due to lower term loans and less bills discounting.

The share of financial results of the associates and joint ventures grew by 42.6% to a profit of RMB 61.4 million (US$ 8.6 million), compared with RMB 43.1 million in 1H 2024. The improvement was mainly driven by higher profits at MTU Yuchai Power Company Limited. 

Income tax expense increased by 13.4% to RMB 116.2 million (US$ 16.2 million) compared with RMB 102.4 million in 1H 2024.  

Net profit attributable to equity holders of the Company increased by 52.2% to RMB 365.8 million (US$ 51.1 million) compared with RMB 240.3 million in 1H 2024.

Basic and diluted earnings per share were RMB 9.75 (US$ 1.36) compared with RMB 5.88 in 1H 2024.

Basic and diluted earnings per share for 1H 2025 and 1H 2024 were based on a weighted average of 37,518,322 shares and 40,858,290 shares, respectively.

Balance Sheet Highlights as at June 30, 2025

  • Cash and bank balances were RMB 7.8 billion (US$ 1.1 billion) compared with RMB 6.4 billion at the end of 2024; 
  • Trade and bills receivables were RMB 12.7 billion (US$ 1.8 billion) compared with RMB 8.8 billion at the end of 2024; 
  • Inventories were RMB 4.7 billion (US$ 655.4 million) compared with RMB 4.7 billion at the end of 2024; 
  • Trade and bills payable were RMB 11.9 billion (US$ 1.7 billion) compared with RMB 8.5 billion at the end of 2024; 
  • Short-term and long-term loans and borrowings were RMB 2.2 billion (US$ 304.6 million) compared with RMB 2.5 billion at the end of 2024.  

Mr. Weng Ming Hoh, President of China Yuchai, commented, “We had strong growth in almost every sales category.  Unit sales of our truck engines rose by 44.3% and our bus engine unit sales increased by 8.9% year over year, outperforming the markets which saw negative growth in both segments.  Unit sales in the important heavy-duty engine segment improved, with truck engine sales up 40.7% and bus engine sales rising 14.4%, despite overall market declines in both segments.  This outperformance demonstrates the solid reliability and performance of our engine products, supported by an extensive service network, and also reflects the positive results of our efforts to expand our customer base and product portfolio.”

“Our off-road segments achieved unit sales growth in all markets segments.  Our marine and generator business was the fastest growing segment in 1H 2025 with a 31.5% increase year over year.  With the MTU-2000 engine and Yuchai-branded VC series diesel engines to be added to the MTU-4000 engine series, our generator engine product portfolio will be better positioned to meet the needs of various end-market users.”

“To further increase our global presence, Yuchai Machinery Power System (Thailand) Co., Ltd. commenced production of the K08 engine.  Additional Yuchai engine models have also started production at this plant.  Through a comprehensive strategic cooperation covering technology licensing, component supply, and related support in Vietnam, we are further deepening our market penetration into the growing ASEAN markets.”

“Our strategy of selling into multiple end markets with a broad and diverse product portfolio continues to create profitable sales growth and free cash flow generation.  To reward our shareholders, a cash dividend of US$ 0.53 per ordinary share for 2024 was paid early in July 2025.  At the end of June 2025, cash and bank balances surpassed US$ 1 billion with lower borrowings.  Our strong financial resources support our current operations and provide investment in new products for our future growth,” Mr. Hoh concluded.

Exchange Rate Information

The Company’s functional currency is the U.S. dollar and its reporting currency is Renminbi.  The translation of amounts from Renminbi to U.S. dollars is solely for the convenience of the reader.  Translation of amounts from Renminbi to U.S. dollars has been made at the rate of RMB 7.1586 = US$1.00, the rate quoted by the People’s Bank of China at the close of business on June 30, 2025.  No representation is made that the Renminbi amounts could have been, or could be, converted into U.S. dollars at that rate or at any other certain rate on June 30, 2025 or at any other date.

Unaudited 1H 2025 Conference Call 

A conference call and audio webcast for the investment community has been scheduled for 8:00 A.M. Eastern Daylight Time on August 8, 2025.  The call will be hosted by the President and Chief Financial Officer of China Yuchai, Mr. Weng Ming Hoh and Mr. Choon Sen Loo, respectively, who will present and discuss the financial results of the Company, followed by a Q&A session.

Analysts and institutional investors may participate in the conference call by registering at: https://register-conf.media-server.com/register/BI9e3a063ea78248039b54c139bea3f91f at least one hour prior to the scheduled start time.  An email reply will be sent with instructions and phone numbers to join the call. 

For all other interested parties, a simultaneous webcast can be accessed on the investor relations section of the Company’s website located at http://www.cyilimited.com. Participants are encouraged to join the webcast at least 10 minutes prior to the scheduled start time.  The recorded webcast will be available on the website shortly after the earnings call.

About China Yuchai International

China Yuchai International Limited, through its subsidiary Guangxi Yuchai Machinery Company Limited (“Yuchai”), is one of the leading powertrain solution providers in China.  Yuchai specializes in the design, manufacture, assembly, and sale of a wide variety of light-, medium- and heavy-duty engines for trucks, buses, pickups, construction and agricultural equipment, and marine and power generation applications.  Yuchai offers a comprehensive portfolio of powertrain solutions, including but not limited to diesel, natural gas, and new energy products such as pure electric, range extenders, and hybrid and fuel cell systems.  Through its extensive network of regional sales offices and authorized customer service centers, Yuchai distributes its engines directly to auto OEMs and distributors while providing after-sales services across China and globally.  Founded in 1951, Yuchai has established a reputable brand name, built a strong research and development team, and achieved a significant market share in China.  Known for its high-quality products and reliable after-sales support, Yuchai has also expanded its footprint into overseas markets.  In 2024, Yuchai sold 356,586 engines, further solidifying its position as a leading manufacturer and distributor of engines in China.  For more information, please visit http://www.cyilimited.com.

Safe Harbor Statement:

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “anticipate”, “project”, “targets”, “optimistic”, “confident that”, “continue to”, “predict”, “intend”, “aim”, “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that may be deemed forward-looking statements.  These forward-looking statements, including, but not limited to, statements concerning China Yuchai’s and the joint venture’s operations, financial performance and condition, are based on current expectations, beliefs and assumptions which are subject to change at any time.  China Yuchai cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world and in China, including those discussed in China Yuchai’s Form 20-Fs under the headings “Risk Factors”, “Results of Operations” and “Business Overview” and other reports filed with the Securities and Exchange Commission from time to time.  All forward-looking statements are applicable only as of the date they are made and China Yuchai specifically disclaims any obligation to maintain or update the forward-looking information, whether of the nature contained in this release or otherwise, in the future.

For more information:

Investor Relations
Kevin Theiss
Tel: +1-212-510-8922
Email: cyd@bluefocus.com

 

— Tables Follow –

 

CHINA YUCHAI INTERNATIONAL LIMITED

UNAUDITED CONSOLIDATED INCOME STATEMENTS

For the first half-years ended June 30, 2025 and 2024

(RMB and US$ amounts expressed in thousands, except per share data)


First Half of 2025


First Half of 2024

RMB ‘000

US$ ‘000

RMB ‘000

US$ ‘000

 

Revenue

13,806,167

1,928,613

10,306,424

1,439,726

 

Cost of sales *

(11,966,703)

(1,671,654)

(8,894,379)

(1,242,475)

 

Gross profit

1,839,464

256,959

1,412,045

197,251

 

Other operating income, net

221,436

30,933

174,110

24,322

 

Research and development expenses

(476,693)

(66,590)

(393,560)

(54,977)

 

Selling, general and administrative expenses *

(962,491)

(134,452)

(755,701)

(105,565)

 

Operating profit

621,716

86,850

436,894

61,031

 

Finance costs

(32,194)

(4,497)

(40,925)

(5,717)

 

Share of results of associates and joint ventures

61,407

8,578

43,075

6,017

 

Profit before tax

650,929

90,931

439,044

61,331

 

Income tax expense

(116,159)

(16,226)

(102,441)

(14,310)

 

Profit for the period

534,770

74,705

336,603

47,021


Attributable to:

 

Equity holders of the Company

365,790

51,100

240,330

33,572

 

Non-controlling interests

168,980

23,605

96,273

13,449

534,770

74,705

336,603

47,021

Net earnings per share

 

– Basic

9.75

1.36

5.88

0.82

 

– Diluted

9.75

1.36

5.88

0.82

 

Unit sales

250,396

192,743

 

 

CHINA YUCHAI INTERNATIONAL LIMITED

SELECTED UNAUDITED CONSOLIDATED FINANCIAL POSITION ITEMS

For the periods ended June 30, 2025 and December 31, 2024

(RMB and US$ amounts expressed in thousands)

 

June 30, 2025
(Unaudited)


December 31, 2024

(Audited)

RMB 000

US$ 000

RMB 000

Cash and bank balances

7,836,207

1,094,656

6,433,593

Trade and bills receivables

12,745,962

1,780,510

8,809,068

Inventories

4,692,035

655,440

4,654,448

Trade and bills payables

11,917,487

1,664,779

8,499,755

Short-term and long-term loans and borrowings

2,180,150

304,550

2,509,800

 


Equity attributable to equity holders of the Company

9,403,187

1,313,551

9,164,625

*Comparatives

Management has reclassified assurance-type warranty expenses from selling and distribution (within
selling, general and administrative expenses) to cost of sales.  The comparative figures in the Income
Statement for the six months ended June 30, 2024, have been adjusted to conform with the current
presentation.  The changes to 1H 2024 comparatives have no impact on the operating profit for
the period of the Group, its financial position or cash flows.

 

 

Truecaller, crosses 100M monthly active users in Middle East and Africa

STOCKHOLM, Aug. 8, 2025 /PRNewswire/ — Truecaller, the leading global platform for verifying contacts and blocking unwanted communications, reached a significant milestone in August as the number of monthly active users (Android and iOS) crossed 100 million in the MEA-region, representing a 19% growth y-o-y.

“With the Middle East and Africa experiencing significant growth in smartphone adoption and mobile data adoption, we’re really happy that we’re able to solve communication problems for individuals and businesses in that region. MEA, like India and many other markets, are mobile first markets with your mobile number being the primary identifier, and Truecaller has always grown organically in such markets. We’re continuing to strengthen our organization and our partnerships in the region, because we believe that the MEA is poised for significant growth for many years ahead,” said Rishit Jhunjhunwala, CEO.

Some of the largest markets in MEA for Truecaller are Egypt, Nigeria, South Africa, Kenya, Algeria, Ghana, and Jordan where Truecaller is used on 20-45% of connected smartphones in those markets.

For more information, please contact:
Andreas Frid, Head of IR & Communication
+46 705 29 08 00
andreas.frid@truecaller.com

About Truecaller

Truecaller (TRUE B) is the leading global platform for verifying contacts and blocking unwanted communication. We enable safe and relevant conversations between people and make it efficient for businesses to connect with consumers. Fraud and unwanted communication are endemic to digital economies. especially in emerging markets. We are on a mission to build trust in communication. Truecaller is an essential part of everyday communication for more than 450 million active users. Truecaller is listed on Nasdaq Stockholm since 8 October 2021. For more information please visit corporate.truecaller.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/truecaller-ab/r/truecaller–crosses-100m-monthly-active-users-in-middle-east-and-africa,c4215814

The following files are available for download:

https://mb.cision.com/Main/20429/4215814/3603228.pdf

Press release 100 m users in MEA 250808

 

RemeGen’s Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

YANTAI, China, Aug. 8, 2025 /PRNewswire/ — On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bispecific antibody, RC148, for the treatment of multiple advanced malignant solid tumors in the US.

RC148 is a PD-1 and VEGF-targeting bispecific antibody, an innovative molecule developed by RemeGen using its bispecific antibody technology platform. Currently, the clinical trials of RC148 as monotherapy and combination therapy for the treatment of advanced solid tumor are proceeding in China.

The clearance of IND application by the FDA is a significant milestone for RC148 which should expedite its global development process.

AXA Signs Cooperation Agreement with Hainan Boao Lecheng Administration

Jointly explore innovative medical insurance services to provide customers with diverse and high-quality healthcare options

HONG KONG, Aug. 8, 2025 /PRNewswire/ — AXA China Region Insurance Company (Bermuda) Limited (“AXA”) formally signed an official cooperation agreement with Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration (“Lecheng Administration”). The partnership aims jointly explore more innovative medical insurance models and leverage the top-tier medical resources of Hainan Boao Lecheng to provide customers with more high-quality cross-border medical options.

The Hainan Boao Lecheng International Medical Tourism Pilot Zone (“the Pilot Zone”) was approved by the State Council[1] in 2013 as the only medical special zone in China, enjoying preferential policies covering licensed medical services, operations, research, and international exchanges. Since approval, the Pilot Zone has attracted leading medical institutions and specialist teams, introducing advanced international treatment protocols, innovative pharmaceuticals, and medical devices into China for trial use – including therapies for rare diseases and cutting-edge cancer treatments. Meanwhile, AXA has partnered with China Biotech Services Holdings Limited to explore Boron Neutron Capture Therapy (“BNCT”), a pioneering initiative now being established within the Pilot Zone.

Janet Lee, Chief Life and Health Insurance Officer, AXA Hong Kong and Macau, said, “We are honoured to have signed a cooperation agreement with the Lecheng Administration. As a pioneer in China’s medical opening-up, Hainan Boao Lecheng benefits from unique policy advantages and strong support from global healthcare resources. This collaboration will enable AXA to explore innovative healthcare solutions and integrate them into our insurance offerings, providing customers with broader access to advanced treatment options. We look forward to deepening our partnership with Lecheng and other stakeholders to develop innovative medical models, enabling more customers to benefit from Lecheng’s licensed medicines, medical devices, and cutting-edge technologies.”

AXA China Region Insurance Company (Bermuda) Limited, AXA International Reinsurance (Shanghai) Company  Limited, together with China Biotech Services Holdings Limited, Qianhai Reinsurance Company Limited, and Gallagher  Insurance Brokers (Hong Kong) Limited, signed a memorandum of understanding to jointly explore and develop Boron  Neutron Capture Therapy and related services, providing customers with diversified treatment options.
AXA China Region Insurance Company (Bermuda) Limited, AXA International Reinsurance (Shanghai) Company Limited, together with China Biotech Services Holdings Limited, Qianhai Reinsurance Company Limited, and Gallagher Insurance Brokers (Hong Kong) Limited, signed a memorandum of understanding to jointly explore and develop Boron Neutron Capture Therapy and related services, providing customers with diversified treatment options.

About AXA Hong Kong and Macau

AXA Hong Kong and Macau is a member of the AXA Group, a leading global insurer with presence in 50 markets and serving 95 million customers worldwide. Our purpose is to act for human progress by protecting what matters.

As one of the most diversified insurers in Hong Kong, we offer integrated solutions across Life, Health and General Insurance. We are the largest General Insurance provider and a major Health and Employee Benefits provider. Our aim is to not only be the insurer to provide comprehensive protection to our customers, but also a holistic partner to the individuals, businesses and community we serve. At the core of our service commitment is continuous product & service innovation and customer experience enrichment, which is achieved through actively listening to our customers’ needs and leveraging and investing in technology and digital transformation.

We embrace our responsibility to be a driving force against climate change and a force for good to create shared value for our community. We are proud to be the first to address the importance of mental health through different products and services and thought leading iconic research. Our overall Sustainability Strategy, with emphasis on climate strategy and biodiversity commitment, is developed based on TCFD recommendations. We are committed to integrating environmental, social and governance factors across our business and strive to contribute to a sustainable future through 3 distinct roles – as an investor, an insurer and an exemplary company.

THIS PRESS RELEASE IS AVAILABLE ON AXA’S WEBSITE: AXA.COM.HK

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed or implied in the forward-looking statements. Please refer to Part 4 – “Risk factors and risk management” of AXA’s Universal Registration Document for the year ended December 31, 2019, for a description of certain important factors, risks and uncertainties that may affect AXA’s business, and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as part of applicable regulatory or legal obligations.

 

Codex Genetics Expands Precision Oncology Portfolio with Cxbladder Genomic Urine Tests

Strategic partnership with Pacific Edge offers Hong Kong clinicians a powerful tool for non-invasive bladder cancer detection and monitoring.

HONG KONG, Aug. 8, 2025 /PRNewswire/ — Codex Genetics, one of the leading precision diagnostics companies in Hong Kong, today announced an exclusive collaboration with Pacific Edge, the developer of the Cxbladder suite of non-invasive genomic urine tests, to bring its advanced bladder cancer diagnostics to hospitals and clinics across Hong Kong.

Product Photo
Product Photo

Under this partnership, Codex Genetics will offer access to Cxbladder’s full range of clinically validated tests—including Cxbladder Detect, Cxbladder Monitor, and Cxbladder Triage—designed to support urologists and oncologists in the risk stratification and surveillance of urothelial bladder cancer. These precision urine-based tests integrate genomic biomarker analysis with clinical algorithms to deliver actionable insights earlier in the patient care pathway.

Importantly, following a February 2025 update, Cxbladder Triage is included in the Microhematuria Guideline[1] issued by the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU). The amended Guideline incorporates language supporting the use of urine-based biomarkers to reduce reliance on cystoscopy and Cxbladder Triage is mentioned specifically, supported with “Grade A” evidence from a randomized controlled trial – the STRATA study[2].

“Our collaboration with Cxbladder reflects Codex’s continued commitment as a leading diagnostics company in Hong Kong to advance precision medicine across Asia,” said Dr. Aldrin Yim, co-founder of Codex Genetics. “Bladder cancer is one of the most expensive cancers to manage due to its high recurrence rate and need for lifelong monitoring. By offering a reliable non-invasive alternative that can reduce the need for cystoscopy, we aim to enhance clinical workflows, allowing clinicians to prioritize time and resources on those who need it the most. This improves the quality of care for patients in both public and private healthcare systems.”

“We are excited to partner with Codex Genetics to expand access to Cxbladder in Hong Kong,” said Dr. Peter Meintjes, CEO of Pacific Edge. “Codex’s regional leadership in precision diagnostics makes them an ideal partner to deliver Cxbladder’s value to clinicians and patients seeking reliable and less burdensome approaches to bladder cancer testing.”

Bladder cancer is the ninth most common cancer worldwide, with high recurrence contributing to its significant clinical and economic burden. Cxbladder has been used in over 100,000 patients globally and is supported by more than 25 peer-reviewed clinical studies demonstrating high sensitivity and negative predictive value. Its adoption can reduce the need for unnecessary invasive procedures and optimize clinical decision-making.

Clinicians in Hong Kong interested in Cxbladder testing may contact Codex Genetics via www.codexgenetics.com for onboarding and access information.

[1] Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. doi: 10.1097/JU.0000000000004490.

[2] Lotan et al. (2024). A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024.

 

Contact:
Whatsapp: (+852) 9837 1345
Phone: (+852) 3008 2560
Email: support@codexgenetics.com